Herpes Zoster Infection in Adults
|Publication: 20/10/2008 --|
|Last review: 22/02/2017|
|Next review: 22/02/2020|
|Approved By: Improving Antimicrobial Prescribing Group|
|Copyright© Leeds Teaching Hospitals NHS Trust 2017|
This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated.
Guideline for the management of herpes zoster infection in adults
Two clinical trials showed a 3 week reducing course of prednisolone had some beneficial effect on acute pain and rash healing. [1, 2] In 1 of these studies, the time to return of normal activity and cessation of analgesics was accelerated in those receiving steroids.  However, there was no significant benefit with regard to treatment of chronic pain. [1, 2] Patients with contraindications to steroids were excluded from these trials, but despite this, adverse effects were reported. A subsequent meta-analysis of five placebo-controlled trials comparing aciclovir and steroid to aciclovir alone did not show a significant difference between the groups in preventing post-herpetic neuralgia . Evidence level A
|Empirical Antimicrobial Treatment|
The principal goals of treatment of herpes zoster are reduction of pain in immunocompetent patients and inhibition of viral replication in immunocompromised patients.
Oral antiviral agents
The results of meta-analysis [8-10] and many - but not all - randomized control trials have demonstrated that antiviral therapy significantly reduces the incidence and duration of prolonged pain. Evidence level A
Aciclovir the first antiviral agent to be used, was studied in four clinical trials [11-15] and at a dose of 800mg 5 times daily started within 72 hours of the rash was shown to reduce the severity and duration of acute pain. Two clinical trials were conducted to compare Famciclovir to placebo, [16, 17] and a single clinical trial of two different doses of valaciclovir compared with aciclovir.  These showed famciclovir and valaciclovir to be effective in accelerating the resolution of post herpetic neuralgia. Evidence level A
There is some but no definite evidence that Famciclovir and valaciclovir may be more effective than Aciclovir , particularly with respect to speed of pain resolution. [18-20] These agents provide higher antiviral activity in blood and may promote patient adherence because they are dosed three rather than five times daily. Evidence level C
There is no clinical trial evidence available on starting antiviral treatment more than 72 hours after the onset of rash. However it may be beneficial in patients who have new vesicle formation, suggesting on-going viral replication, and in those patients with complications. Since the risks of treatment with antiviral drugs is minimal, it is recommended to consider treatment in patients with new vesicle formation more than 72 hours after onset of rash and in patients with neurological or ocular complications. Evidence level C
Recommendation: (Immunocompetent patients)
Treat with oral Aciclovir 800mg five times a day
Neurological or ocular complications:
Treatment duration is 7 days but longer courses may be required with ocular or neurological complications
Initial clinical trials of IV aciclovir in immunocompromised patients showed that treatment halts disease progression and reduces the duration of viral replication.  Subsequent trials showed that IV aciclovir is also effective at preventing virus dissemination. [22,23]
The dose should be calculated on ideal body weight to avoid over dosage of obese patients and is reduced in renal impairment (creatinine clearance <50ml /minute). When infection is controlled, i.e. the patient is systemically well and no new vesicles have appeared for 24 hours, then oral medication can be substituted for the duration of the course. There is limited clinical trial data on the use of Famciclovir and valaciclovir in immunocompromised patients, but growing clinical experience suggests that these medications are safe and effective in this setting. [24,25]
For patients who are less severely immunosuppressed, oral antiviral therapy with close observation is a reasonable option. The higher plasma concentrations of Famciclovir and valaciclovir along with simpler dose regime favours their use over oral aciclovir.
Recommendation (immunocompromised patients):
Please contact microbiology if the patient is not responding to the recommended antimicrobial regimens.
To improve the diagnosis and management of herpes zoster virus (HZ) infection in adults
|Target patient group:||Adults with suspected herpes zoster infection (shingles)|
|Target professional group(s):||Secondary Care Doctors
- Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125:376–83.
- Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330:896–900
- He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008
- Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36:877–82.
- Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr;142(3):209-17
- Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94:215–24.
- Dworkin RH, Johnson RW et al. Recommendations for the management of herpes zoster. Clin infect Dis 2007;44:S1-26
- Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22:341–7.
- Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997; 157:909–12.
- Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl 1991; 78:62–8.
- McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. BMJ 1986; 293: 1529 – 32.
- Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85 (Suppl 2A): 84 – 9.
- Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; Suppl 1:93 – 6.
- Wood MJ, Organ PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85(Suppl 2A): 79 – 83.
- Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93 – 5.
- Tyring S, Barbarash RA, Nahlik JE, et al.Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:89–96.
- Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of Famciclovir, age, rash severity and acute pain in herpes zoster patients. J Infect Dis 1998; 178(Suppl 1):S76–80.
- Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546–53.
- Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4:241–6.
- Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A, Paulet C, Candaele D. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol. 2004;29(4):248
- Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS. Acyclovir treatment of herpes zoster infections use in children undergoing bone marrow transplant. JAMA 1982; 247:2132–6.
- Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314:208–12.
- Meyers JD, Wade JC, Shepp DH, Newton B. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984; 37:571–4.
- Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of Famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19:13–22
- Brentjens MH, Torres G, He J, Lee PC, Tyring SK. A double-blind randomized study of the use of 2 grams vs. 1 gram valacyclovir TID for 7 days in the treatment of acute herpes zoster in immunocompromised individuals. Presented at: Annual Meeting of the American Academy of Dermatology (San Francisco, March 2003).
- Public Health England. The Green Book: Chapter 28a Shingles (herpes zoster). February 2016
A. Meta-analyses, randomised controlled trials/systematic reviews of RCTs
B. Robust experimental or observational studies
C. Expert consensus.
Improving Antimicrobial Prescribing Group
LHP version 1.0
Equity and Diversity
The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.